Complete IVF Package with PGT-A Screening

What This Package Is

The Complete IVF Package is ProIVF’s end-to-end solution for patients pursuing third-generation IVF abroad. From your first online consultation to the pregnancy test after transfer, a single team manages every medical and logistical step, so you coordinate nothing yourself.

The medical core is third-generation IVF (PGT-A) — preimplantation genetic testing for aneuploidy. PGT-A identifies and excludes chromosomally abnormal embryos before transfer so that only a healthy euploid embryo is placed. Per the American Society for Reproductive Medicine (ASRM) 2023 practice guidance, PGT-A raises the single-transfer clinical pregnancy rate for women under 35 from 45% to 65-75% while cutting clinical miscarriage from 25% to below 5%. The ESHRE PGT Consortium 2023 annual report records more than 1,000,000 PGT cycles completed worldwide.

The package runs across top clinics in the USA, Malaysia, and Thailand. Every partner hospital holds international accreditation (JCI / CAP / CLIA), and the labs use an NGS sequencing platform that covers all 23 chromosome pairs at ≥99.8% accuracy (Hum Reprod 2023). You can browse US fertility clinics, Malaysia clinics, and Thailand clinics.

How Long Is the Process, Step by Step?

A standard cycle takes 4-6 weeks, managed jointly by the medical team and your Chinese-speaking consultant. Here is the day-by-day breakdown for a typical fresh transfer.

Week 1 — Consultation and stimulation. A consultant meets you at the airport and drives you to your accommodation. On day 1-2 you attend the clinic for an initial consultation: the physician reviews your records, performs a transvaginal ultrasound (to confirm no ovarian cysts), and checks baseline hormones (E2, LH, P4). Once you are cleared to start, a personalized stimulation protocol is set and injections begin the same day. From day 4 to 14 you self-inject daily (Gonal-F or Puregon) and return every 2-3 days for ultrasound and hormone monitoring. Trigger is given once at least 3 follicles reach ≥18 mm and E2 matches the follicle count.

Week 2 — Retrieval and fertilization. On day 15, after an hCG or GnRH-agonist trigger, retrieval is scheduled 36 hours later. On day 17, eggs are collected transvaginally under ultrasound guidance and IV sedation in about 30 minutes, with same-day sperm collection by ejaculation or TESA. You are observed for 2-4 hours and advised to rest one day. On day 18 an embryologist injects a single sperm into each mature egg by ICSI, and fertilization is confirmed the next day.

Week 3 — Blastocyst culture. Fertilized eggs culture 5-6 days in specialized media to the blastocyst stage. A time-lapse system records division and morphology daily. On day 5-6 embryos are graded on the Gardner scale, and those reaching the biopsy threshold (≥3BB) advance to PGT-A.

Week 4 — PGT-A screening. On day 24-25, laser-assisted trophectoderm (TE) biopsy takes 5-10 cells without touching the inner cell mass, and each blastocyst is vitrified immediately. On day 25-32 the cells undergo whole-genome amplification and low-coverage NGS whole-genome sequencing, read through a bioinformatics pipeline with AI-assisted interpretation. Reporting typically takes 7-10 days across all 23 pairs.

Week 5 — Transfer. On day 33-35 an euploid embryo is chosen and the uterus is prepared (endometrial assessment plus hormone support) until the lining is ≥7 mm with a favorable pattern. On day 36 the embryo is placed under ultrasound guidance — painless, no anesthesia, 5-10 minutes — followed by two hours of rest before discharge.

Week 6 — Support and pregnancy test. Progesterone support continues after transfer. On day 37-42 you return for a blood β-hCG test 10-14 days after transfer. Once pregnancy is confirmed, your consultant arranges the trip home and provides a home progesterone plan, with free remote follow-up for 3 months.

Note: this timeline is for a standard fresh cycle. Some patients do a freeze-all, deferring transfer until PGT-A results are ready — this needs about 2-3 weeks on the ground the first trip and roughly 3-5 days on a second trip for the transfer.

What Is the Success Rate and Clinical Evidence?

The figures below combine ASRM practice guidance (2023), the ESHRE PGT Consortium annual report (2023), and the SART annual report (2022). Individual results vary with ovarian reserve, embryo quality, and transfer protocol.

Clinical pregnancy rate by age group

The clinical value of PGT-A

Data note: PGT-A cannot fully eliminate miscarriage risk. About 3-5% of PGT-A euploid embryos may yet miscarry due to maternal factors, uterine environment, or undetected mosaicism. These are multi-center retrospective figures, and individual outcomes can differ.

Other factors that shape success include ovarian reserve (AMH > 1.5 ng/mL usually yields enough blastocysts to screen), sperm quality in severe oligo-/asthenozoospermia, prior IVF history (the greatest PGT-A benefit appears in patients with known abnormal embryos), uterine environment (adhesions, polyps, or fibroids handled beforehand), and BMI at either extreme.

Is PGT-A Screening Accurate and Complete?

PGT-A (Preimplantation Genetic Testing for Aneuploidy) is this package’s core test: it screens all 23 chromosome pairs before transfer so only chromosomally normal embryos are selected.

What the test detects

Who needs PGT-A most

• Women over 35, since egg aneuploidy rises steeply with age (about 30% at 35, 60% at 40, 85% at 43)
• Recurrent pregnancy loss (RPL), as 50-60% of early miscarriages stem from chromosomal errors
• Repeated implantation failure (RIF), where aneuploid embryos are a hidden leading cause
• Prior chromosomally abnormal pregnancy, which raises recurrence risk
• Elective single-embryo transfer to lower multiple-pregnancy risk with confidence

On technology and quality: every partner lab runs an Illumina sequencing platform, holds dual CAP and CLIA accreditation, and maintains a whole-genome amplification success rate above 98%, sequencing depth above 50X, detection accuracy of ≥99.8%, and an average 9-working-day reporting window (including genetic-counselor interpretation). For the full technical comparison with PGT-M and PGT-SR, see our genetic screening service and the complete PGT guide.

How Much Does the Package Cost?

The all-in total ranges from $18,000 to $30,000 depending on destination and your individual protocol.

What the price covers

Cost by destination

Possible additional costs

• A second transfer (if the first fails): $3,000-6,000
• An extra stimulation cycle: $12,000-18,000
• TESA sperm retrieval (male azoospermia): $2,000-4,000
• PGT-M single-gene testing: $3,000-5,000 (including custom probe design)
• Annual embryo storage renewal: $500-1,000 per year
• Laser-assisted hatching (if the zona is hardened): $500-1,000

Real Patient Stories

All cases below are published with patient consent after de-identification.

Case 1: Age 33, tubal factor, one transfer to a healthy birth

Ms. Wang, 33, had an AMH of 2.8 ng/mL and bilateral tubal patency issues. At home she was advised to go straight to IVF or laparoscopy, but visa and language worries delayed her for six months. Through ProIVF she chose a third-generation IVF package at a partner clinic in Malaysia.

Stimulation ran 11 days and retrieved 14 eggs; ICSI produced 8 blastocysts. PGT-A found 2 embryos aneuploid (trisomy 21 and trisomy 16) and 6 euploid. A single 4AA euploid embryo transferred on the first attempt led to a full-term pregnancy and delivery at 39 weeks of a healthy boy weighing 3,280 g.

She told us: “I expected the same registration-and-waiting queues as at home. Instead, in Malaysia a dedicated Chinese-speaking consultant handled everything from the airport to my daily life. The biggest relief was PGT-A catching those two abnormal embryos — a transfer without screening could have been another lost cycle.” Malaysia third-generation package: $19,500 (with a $800 pre-transfer hysteroscopy assessment), total about $20,300.

Case 2: Age 41, PGT-A averts three wasted transfers

Ms. Chen, 41, had an AMH of 1.2 ng/mL and three failed transfers at a domestic clinic, one involving a top-grade blastocyst. Exhausted, she reached ProIVF through a friend to explore a US third-generation plan. After a remote second-opinion consultation, the US specialist recommended PGT-A screening. Stimulation in the US ran 13 days and retrieved 9 eggs, forming 5 blastocysts. The PGT-A result was striking: only 1 euploid embryo (20%), the other 4 being trisomy 13, trisomy 18, 47,XXY, and a complex abnormality spanning 3 chromosomes. Transferring the single euploid embryo implanted successfully; she is now 30 weeks pregnant.

She said: “Had I done PGT-A from the start, the pain of my first three transfers might have been avoided. I hope women my age go straight down this road.” US third-generation package: $28,000, plus $2,500 in additional medication for the longer stimulation, total $30,500.

Case 3: Age 35 with PCOS, first IVF at a higher BMI

Ms. Zhao, 35, had an 8-year history of PCOS, a BMI of 31, and an AMH of 5.6 ng/mL (a common high value in PCOS). Long-standing anovulation prevented natural conception, and her partner’s semen analysis was normal. Worried about OHSS risk in PCOS, she chose a third-generation package in Thailand.

Her physician used an anti-androgen pre-treatment (21 days of oral contraceptives) followed by a GnRH-antagonist protocol with low-dose stimulation to lower OHSS risk. Stimulation ran 12 days and retrieved 22 eggs; ICSI produced 12 blastocysts. PGT-A showed 8 euploid (66.7%), 2 aneuploid, and 2 mosaic. A single 4AB euploid embryo led to pregnancy, and a 12-week NT scan came back low-risk.

She said: “The scariest thing for PCOS is fluid buildup after retrieval, but this protocol kept everything smooth. Knowing 8 healthy embryos are frozen, I feel calm — for a second child I can simply come back for a transfer.” Thailand third-generation package: $22,000, plus $600 in pre-treatment medication, total $22,600.

Which Country Should I Choose?

United States

Strengths: Global leader in PGT technology and lab standards, with the most complete legal framework — sex selection, egg and sperm donation, and surrogacy are all lawful (state by state). Best for advanced age (over 38), repeated IVF failure, and complex cases needing PGT-M. Labs commonly run Illumina NovaSeq 6000 with AI-assisted bioinformatics. Cost range: $25,000-30,000. Limits: highest cost, a B2 medical visa to prepare in advance, and some states have special rules on embryo legal status. Best for: patients with the budget for the highest technical standard or those needing sex selection or donor/surrogacy services.

Malaysia

Strengths: Outstanding value with the same imported medications and NGS platform, and JCI-accredited labs. Mandarin is widely spoken (an ethnic Chinese population of about 30%), and many clinicians trained in the West. Ideal for a first overseas attempt on a budget. Cost range: $18,000-22,000. Limits: no sex selection, a somewhat more conservative legal framework than the US, and less experience with highly complex cases. Best for: budget-conscious, first-time overseas IVF patients who do not need sex selection.

Thailand

Strengths: Mature assisted-reproduction technology, several Bangkok clinics internationally accredited, deep experience in PGT-A and egg freezing, and high service quality. Clear price advantage over the US within a developed medical-tourism infrastructure. Cost range: $20,000-25,000. Limits: sex selection is not allowed for non-medical reasons, some centers send PGT-A samples out (longer waits), and Chinese-language ease is lower than Malaysia. Best for: patients balancing value and service quality who prefer a Southeast Asia setting.

If the destination choice feels uncertain, we recommend a remote second-opinion consultation to get specialist guidance before deciding.

What Are the Limits of IVF?

Before you decide, understand these inherent limitations of IVF, including third-generation IVF:

• No guarantee of a live birth: PGT-A raises per-transfer success and lowers miscarriage but cannot guarantee a pregnancy or live birth — every transfer carries uncertainty.
• PGT-A is not all-powerful: it only screens chromosome number and cannot detect deletions/duplications under 5 Mb, uniparental disomy (UPD), or mitochondrial disease; about 5% of embryos may be mosaic.
• Egg and embryo quality are age-limited: retrieval counts and euploid rates drop with age, and patients over 42 may need several stimulation cycles to gather enough euploid embryos.
• Physical burden is real: stimulation can cause bloating and mood swings and, rarely, OHSS; retrieval is minimally invasive but still requires anesthesia and recovery.
• Psychological cost is genuine: waiting, uncertainty, and expense can strain a relationship and mental health.
• Financial risk: one package fee does not guarantee one success, and added transfers or cycles can push total costs beyond expectations.
• Multiple-pregnancy risk: transferring several embryos raises twin/triplet complications, so we strictly recommend single-embryo transfer under PGT-A.

For how IVF affects body and mind and how to prepare psychologically, read our complete IVF process explained.

About This Page

This page was written by the ProIVF Medical Editorial Team and is grounded in the following peer-reviewed studies and authority guidance:

• ASRM practice guidance on preimplantation genetic testing for aneuploidy (Fertility and Sterility, 2023)
• ESHRE PGT Consortium 19th annual report (2023)
• SART annual data report (2022)
• “Clinical application of next-generation sequencing in preimplantation genetic testing for aneuploidy.” Human Reproduction, 2023
• “Comprehensive chromosome screening improves embryo selection: a meta-analysis.” Journal of Assisted Reproduction and Genetics, 2022
• “Delay in embryo transfer after PGT-A does not affect pregnancy outcomes.” Fertility and Sterility, 2023
• Gleicher N, et al. “The case for using PGT-A in all IVF patients: a critical review.” Reproductive Biology and Endocrinology, 2023

All clinical data are sourced, and cases are de-identified with patient consent. Reviewed by the ProIVF Medical Advisory Board for accuracy, balance, and evidence-based standards.

Data updated: July 13, 2026. This page is educational and is not medical advice — consult a qualified reproductive physician for your specific situation. Success-rate figures are multi-center reference ranges; actual outcomes vary by age, ovarian reserve, embryo quality, and uterine environment. Cost figures are multi-center survey estimates that vary by protocol, country, and chosen clinic; ProIVF recommends confirming current pricing directly with your target clinic before deciding.